Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: placebo
Drug: insulin degludec
Drug: liraglutide

First Posted Date: 2012-08-14

Last Posted Date: 2017-09-25

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 346

Registration Number: NCT01664247

Locations: 🇬🇧
Novo Nordisk Investigational Site, Stevenage, United Kingdom

Safety and Efficacy of Biphasic Insulin Aspart 50 in Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: biphasic human insulin 50
Drug: biphasic insulin aspart 50

First Posted Date: 2012-07-26

Last Posted Date: 2017-02-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 83

Registration Number: NCT01650129

Locations: 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan

Safety and Efficacy of Insulin Aspart in Type 2 Diabetes

Phase 4

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin aspart

First Posted Date: 2012-07-25

Last Posted Date: 2012-07-25

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 123

Registration Number: NCT01649570

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis

Phase 2

Completed

Conditions: Inflammation
Rheumatoid Arthritis

Interventions: Drug: placebo
Drug: NNC0114-0006

First Posted Date: 2012-07-23

Last Posted Date: 2017-02-07

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 62

Registration Number: NCT01647451

Locations: 🇪🇸
Novo Nordisk Investigational Site, Sevilla, Spain

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Phase 2

Terminated

Conditions: Inflammation
Rheumatoid Arthritis

Interventions: Drug: NNC0109-0012
Drug: placebo

First Posted Date: 2012-07-10

Last Posted Date: 2018-09-05

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 298

Registration Number: NCT01636843

Locations: 🇺🇦
Novo Nordisk Investigational Site, Zaporizhzhia, Ukraine

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Phase 2

Terminated

Conditions: Inflammation
Rheumatoid Arthritis

Interventions: Drug: placebo
Drug: NNC0109-0012

First Posted Date: 2012-07-10

Last Posted Date: 2018-09-05

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 239

Registration Number: NCT01636817

Locations: 🇬🇧
Novo Nordisk Investigational Site, Wolverhampton, United Kingdom

A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects

Phase 1

Terminated

Conditions: Haemophilia A
Congenital Bleeding Disorder
Healthy

Interventions: Drug: NNC172-2021

First Posted Date: 2012-06-29

Last Posted Date: 2019-05-15

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 4

Registration Number: NCT01631942

Locations: 🇬🇧
Novo Nordisk Investigational Site, Harrow, United Kingdom

French Observational Survey to Assess Hypoglycaemia in Insulin-treated Diabetic Patients

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2

Interventions: Drug: insulin

First Posted Date: 2012-06-26

Last Posted Date: 2017-01-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 4424

Registration Number: NCT01628341

Locations: 🇫🇷
Novo Nordisk Investigational Site, Paris La défense cedex, France

A Trial Investigating the Absolute Bioavailability of Insulin Degludec in Healthy Subjects

Phase 1

Completed

Conditions: Healthy
Diabetes

Interventions: Drug: insulin degludec

First Posted Date: 2012-06-20

Last Posted Date: 2015-02-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 18

Registration Number: NCT01623375

Pharmacokinetics of Biphasic Insulin Aspart 50 and 70 in Japanese Healthy Volunteers

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: biphasic insulin aspart 50
Drug: biphasic insulin aspart 70

First Posted Date: 2012-06-15

Last Posted Date: 2017-01-05

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT01620333

Locations: 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy